1. In Vivo
  2. >>Business Strategy

As Time Ticks, Industry Edges Closer To The Big Patent Cliff

 
• By Jessica Merrill and Edwin Elmhirst

Big pharma manufacturers are approaching a period that will be marked by the loss of exclusivity of many big-selling brands. All of the players are looking for ways to navigate the loss of revenues.

Clock
• Source: Shutterstock

The pharmaceutical industry is moving closer to a big and extended patent cliff, a period of time from 2025 to the end of the decade when many of the industry’s biggest revenue generating products are facing loss of exclusivity (LOE).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.